Study on Risk Factors and Incidence of Ganciclovir-Resistant Cytomegalovirus Infection in Adults After Organ or Stem Cell Transplant

What this Trial Is About

Researchers are investigating the risk factors and incidence of ganciclovir-resistant or refractory GCV-RR cytomegalovirus CMV infections in adults who have received solid organ transplants SOT or hematopoietic stem cell transplants HSCT. CMV is a serious infection that can cause significant health problems in these transplant recipients. This observational study aims to better understand how often GCV-RR CMV occurs and which factors contribute to its development, to guide future prevention and management efforts. This multicenter retrospective study observes adult SOT and HSCT patients who developed CMV infections treated with ganciclovir or valganciclovir. The study does not involve new treatments but collects existing clinical and laboratory data on these patients to assess the incidence of resistant infections and related risk factors. It compares patients with GCV-RR CMV to those with ganciclovir-susceptible GCV-S CMV to evaluate differences in outcomes and treatment responses. Participants medical records are reviewed to gather information on CMV episodes, viral resistance, treatment effectiveness, clinical cure, graft outcomes, and hospital stays over about one year. The study monitors outcomes like mortality, need for intensive care, and hospital readmissions. Data on therapeutic management of GCV-RR CMV are also collected. The studys findings aim to improve understanding of GCV-RR CMV and help design better strategies for patient care.

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients